Lv510
980 积分 2023-05-08 加入
Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
15小时前
求助中
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial
17小时前
待确认
Long-term safety, durability of response, cessation and switching of biologics
2天前
已完结
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma
11天前
已完结
中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识
12天前
已完结
中国中老年居民高血压、糖尿病和血脂异常共病现状及影响因素研究
12天前
已完结
代谢相关（非酒精性）脂肪性肝病防治指南（2024年版）
12天前
已完结
Novel inhibitors of STAT3: an updated patent review (2022–present)
13天前
已完结
CCR8在肿瘤免疫治疗中的研究进展
14天前
已完结
Seven Biopharma Trends to Watch in 2025
27天前
已关闭
皖公网安备34019202002308
